Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (Nasdaq: XFOR) announced plans to report its financial results for Q2 2020 on July 30, 2020. The earnings call will provide insights into recent business highlights and will take place at 8:30 a.m. ET. The company focuses on treating diseases linked to CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, undergoing multiple clinical trials, including a Phase 3 trial for WHIM syndrome. Interested parties can access the live webcast via the company's investor relations webpage.
X4 Pharmaceuticals presented encouraging data from its ongoing Phase 2 trial of mavorixafor for WHIM syndrome, demonstrating significant reductions in yearly infection rates and wart burden. The trial observed sustained efficacy and safety trends for up to 28.6 months, with the 400 mg daily dose showing effective results in improving clinical outcomes. The data supports the ongoing pivotal Phase 3 trial, with top-line results anticipated in 2022. The company estimates WHIM syndrome affects over 3,500 individuals in the U.S., highlighting a crucial unmet medical need.
X4 Pharmaceuticals (Nasdaq: XFOR) has promoted Renato Skerlj, Ph.D., to Chief Scientific Officer. Dr. Skerlj, a co-inventor of the lead drug candidate mavorixafor, joined X4 in 2019 and has significantly contributed to the company's research efforts. His leadership is crucial as the company advances mavorixafor through clinical trials for WHIM syndrome and genetically-defined blood cancers. X4 continues to focus on therapies targeting the CXCR4 pathway for rare diseases, with ongoing global Phase 3 trials for mavorixafor.
X4 Pharmaceuticals (Nasdaq: XFOR) announced it will host a conference call on June 12, 2020, to discuss clinical efficacy and safety data from the ongoing Phase 2 trial of mavorixafor for WHIM syndrome. The data will be shared at the 25th European Hematology Association Annual Congress from June 11-14, 2020. Mavorixafor, a first-in-class treatment, is currently evaluated in a global Phase 3 trial for WHIM syndrome and in additional Phase 1b trials for other conditions. The conference call can be accessed via phone or webcast.
X4 Pharmaceuticals (Nasdaq: XFOR) announced an inducement award for new employees on May 29, 2020, as part of its 2019 Inducement Equity Incentive Plan. A total of 55,200 options to purchase common stock at an exercise price of $8.52 per share were granted. These options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment. X4 is known for developing therapies targeting CXCR4 pathway dysfunction, focusing on rare diseases, with its lead candidate, mavorixafor, currently in Phase 3 trials.